Cochlear delivers $2.34B in FY26 sales revenue

• Cochlear generated $2.34 billion in full-year sales revenue, alongside an underlying net profit of $322.4 million.
• Statutory net profit fell 62% to $147.3 million, while the stock price reacted negatively to the overall results.
• The business stated it expects an FY27 underlying net profit of $330–350 million, prioritising cost discipline and targeted investments.

Cochlear (ASX:COH) reported a 2% constant currency sales increase to $2.34 billion and $322.4 million underlying profit.

The financial outcome matched the upper end of revised April guidance despite flat cochlear implant revenues.

Statutory net profit fell 62% to $147.3 million due to cloud expenses and fair value investment losses.

Cochlear implant units increased 5% to 56,692, with revenue flat in constant currency at $1.4 billion.

The company stated it expects 2027 underlying net profit of $330–350 million alongside low single-digit sales growth.

Following the announcement, the Cochlear share price was down at $131.25.

The business recently launched the Cochlear Nucleus Nexa System to improve patient experience and support strategic growth.